IP Library › Granted Patent US 11,174,273
Granted Patent B2
US 11,174,273 · App. 16/264,194 · Granted Nov 16, 2021

Quinazoline analogs as receptor tyrosine kinase inhibitors

Inventors: Eli Wallace (Richardson, TX); George Topalov (Pittsburgh, PA); Joseph Lyssikatos (Piedmont, CA); Alexandre Buckmelter (Westford, MA); Qian Zhao (El Cerrito, CA)
Assignee: Array Biopharma Inc.
C07D498/10A61P29/00A61P35/00C07D239/94C07D401/12C07D413/12C07D413/14C07D417/14C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,174,273
App. No.
16/264,194
Granted
Nov 16, 2021
Kind
B2
Abstract

The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Claims (2)

1. A method of inhibiting the activity of ErbB2 comprising administering an effective amount of a compound selected from the group consisting of:

2. The method of claim 1 , wherein the compound is:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2020
From: WALLACE, ELI; TOPALOV, GEORGE; LYSSIKATOS, JOSEPH; BUCKMELTER, ALEXANDRE; ZHAO, QIAN
To: ARRAY BIOPHARMA INC.
Reel/Frame 051453/0991 →
Continuity (7)
Continuation 15606928 · May 26, 2017
Continuation 13607016 · Sep 7, 2012
Continuation 12249421 · Oct 10, 2008
Division 10914974 · Aug 10, 2004
Continuation In Part 10642440 · Aug 14, 2003
Provisional Application 60551718 · Mar 10, 2004
Related Publication 20190161500A1 · May 30, 2019